Endocrine Abstracts

Introduction: The assessment of the glycemic regulation of patients with Type 1 Diabetes Mellitus is necessary, in order to design an individualized treatment plan, to control the complications resulting from hyper- or hypoglycemia. For this purpose, we use HbA1c, continuous glucose monitoring (CGM) with TIR (time in range), or blood glucose monitoring (BGM). However, none of the above, can be applied without the cooperation of the patient, which for various reasons, often bec...

Introduction: Paragangliomas are rare neuroendocrine neoplasms originating from the chromaffin cells of the neural crest and projecting from the extra-adrenal paraganglia. For more than 30% of patients with paragangliomas there is a genetic predisposition. According to W.H.O. paragangliomas should be treated as potentially metastatic diseases. We describe the case of a patient with a paraganglioma and a pathogenic variant in the SDHB gene.Case Presentati...

Fluasterone (16-α-fluoro-5-androsten-17-one) is a structural analogue of dehydroepiandrosterone (DHEA) that retains DHEA clinical properties without its androgenic effects. In animal models, fluasterone exhibits DHEA-like effects, including anti-inflammatory, anti-proliferative, and anti-diabetic properties but is consistently more potent than DHEA. An orphan-drug designation for fluasterone has been granted by the FDA for treatment of Cushing’s syndrome (CS), includ...